Influence of pathogenic filaggrin variants on dupilumab treatment in atopic dermatitis.
Julia Clabbers, Celeste Boesjes, Lotte Spekhorst...
https://pubmed.ncbi.nlm.nih.gov/38272373/Actively Recruiting
Led by UMC Utrecht · Updated on 2025-03-28
1200
Participants Needed
14
Research Sites
N/A
Total Duration
Researchers are collecting real-world data to evaluate the effectiveness and safety of new systemic treatments such as biologics and Janus kinase inhibitors in patients with atopic dermatitis. The BioDay Registry also studies the impact of these treatments on related allergic conditions like food allergies, asthma, and conjunctivitis. This observational registry gathers information from multiple centers to better understand treatment outcomes in daily clinical practice. Participants include both adults and children receiving new systemic therapies for their atopic dermatitis. There is no assigned treatment in the study since it is observational instead, data is collected as patients receive their prescribed medications. The registry includes modules for atopic comorbidities and monitors patients over time to capture the effects of treatment in routine care. Participants will provide data through questionnaires and clinical assessments at multiple timepoints, including baseline, 16 weeks, 1 year, 2 years, and annually up to 5 years. Researchers track changes in disease symptoms, side effects, drug continuation rates, laboratory results, comorbid conditions, and any dose adjustments. This long-term follow-up aims to improve understanding of treatment safety and effectiveness in everyday settings.
CONDITIONS
BioDay Registry: Data Collection Regarding the Use of New Systemic Treatment Options in Patients with Atopic Dermatitis
M
Marlies de Graaf, MD, PhD
I
Ilona de Ridder
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
UMC Utrecht
Lead Sponsor
Academisch Ziekenhuis Groningen
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Duration - Up to 5 years
Participants who undergo routine care with new systemic treatments for atopic dermatitis are observed over time to assess treatment effectiveness, side effects, and other health measures.
Yearly visits
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Julia Clabbers, Celeste Boesjes, Lotte Spekhorst...
https://pubmed.ncbi.nlm.nih.gov/38272373/UMC Utrecht
Lead Sponsor
Academisch Ziekenhuis Groningen
Collaborating Sponsor